Božić Bojan D J, Rogan Jelena R, Poleti Dejan D, Trišović Nemanja P, Božić Biljana D J, Ušćumlić Gordana S
Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, Belgrade, Serbia.
Chem Pharm Bull (Tokyo). 2012;60(7):865-9. doi: 10.1248/cpb.c12-00185.
A series of novel Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes with oxaprozin (Hoxa), a non-steroidal anti-inflammatory drug, has been synthesized. The drug and complexes have been characterized by elemental and thermogravimetric (TG) analysis, Fourier transform (FT)-IR, 1H-NMR, 13C-NMR, UV-Vis spectroscopy and magnetic susceptibility measurements. The (pseudo)octahedral geometry has been proposed for all complexes based on electronic spectra and magnetic moments. With exception of the Cu(II) complex, where bridging bidentate mode of COO groups has been found, FT-IR spectra confirmed chelately coordinated COO groups in the other complexes. The general formula of the complexes is [M(H2O)2(oxa)2 ·χH2O, with χ=2 for M=Mn, Co and Ni and χ=1.5 for Zn. The binuclear Cu(II) complex, [Cu2(H2O)2(OH)(oxa)3]·2H2O, has strong Cu-Cu interactions of antiferromagnetic type. The complexes and Hoxa did not exhibit the cytotoxic effect to peritoneal macrophages. For the first time these complexes have been tested for their in vitro antiproliferative activity against human colon and breast cancer cell lines, HCT-116 and MDA-231, respectively. For all investigated compounds significant antiproliferative effects have been observed. Ni(II) complex has been shown to be a promising antiproliferative agent exerting excellent activity against HCT-116 even in nanomolar concentrations.
合成了一系列新型的与非甾体抗炎药恶丙嗪(Hoxa)形成的锰(II)、钴(II)、镍(II)、铜(II)和锌(II)配合物。通过元素分析、热重(TG)分析、傅里叶变换(FT)-红外光谱、1H-核磁共振、13C-核磁共振、紫外可见光谱和磁化率测量对药物及配合物进行了表征。基于电子光谱和磁矩,为所有配合物提出了(伪)八面体几何结构。除了发现铜(II)配合物中羧酸根基团为桥连双齿模式外,FT-红外光谱证实其他配合物中羧酸根基团为螯合配位。配合物的通式为[M(H2O)2(oxa)2·χH2O,其中M = Mn、Co和Ni时χ = 2,M = Zn时χ = 1.5。双核铜(II)配合物[Cu2(H2O)2(OH)(oxa)3]·2H2O具有强反铁磁类型的Cu-Cu相互作用。这些配合物和Hoxa对腹腔巨噬细胞未表现出细胞毒性作用。首次对这些配合物针对人结肠癌细胞系HCT-116和乳腺癌细胞系MDA-231的体外抗增殖活性进行了测试。对于所有研究的化合物,均观察到显著的抗增殖作用。已表明镍(II)配合物是一种有前景的抗增殖剂,即使在纳摩尔浓度下对HCT-116也具有优异的活性。